The US Food and Drug Administration (FDA) just green-lighted Filament Health Corporation, a clinical-stage company in the natural psychedelic medicine development business, to do a study on the effects of certain psychedelic drugs. Filament has already created around 70 strains of psychedelic mushrooms to be used for research, and they were able to raise a cool $2.5 million to continue studying the use of psychedelics through stabilized formulas. These would offer patients the benefits of better bioavailability, consistency, and a quicker onset as well as a reduction in side effects.
A land-rooted look at the growers reshaping cannabis through living soil, ecological intelligence and regenerative…
Jowell & Randy member Randy is expanding into cannabis with La Zaza, a brand built…
wo of the most popular autoflowering takes on the Cookies family are Auto Girl Scout…
Jamaica has introduced two new special permits designed to help traditional growers and small farmers…
Italy has extensive opioid use, established illicit drug markets and criminal organizations capable of moving…
A strange prophecy sends an isolated artist on a three-day collision with grief, love, creativity,…